QIPB in Inguinal Hernia

ConditionPostoperative Pain

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-65

SponsorKonya City Hospital

About this trial

Inguinal hernia repair is one of the most commonly performed surgical procedures. It is generally performed under regional anesthesia techniques, such as local anesthesia, peripheral nerve blocks, or neuraxial anesthesia (spinal or epidural anesthesia), or under general anesthesia. Despite various available analgesic regimens, numerous studies have demonstrated that postoperative pain control remains inadequate. Opioids, nonsteroidal anti-inflammatory drugs, and analgesics are frequently used for postoperative pain management. However, these medications are associated with uncertain efficacy and undesirable side effects. Pain is a critical factor in the postoperative period, contributing to delayed ambulation and paralytic ileus, ultimately hindering early discharge.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18-65 years

Undergoing elective,

unilateral laparoscopic inguinal hernia repair

Receiving general anesthesia

Disqualifiers

Patients who refuse to provide consent

Patients with contraindications to regional anesthesia

Patients with impaired consciousness

Patients with coagulopathy

Trial design

Design model

Parallel

Treatments tested in this trial

Quadro iliac plane block
Other intervention
Patients in Group Q will be placed in the lateral position. A low-frequency convex transducer and a 100-mm block needle will be used. Following sterilization, the transducer will be placed parasagittally at the distal attachment of the quadratus lumborum muscle to the iliac crest. The iliac crest and quadratus lumborum muscle will be visualized, with the erector spinae muscle above and the psoas major muscle below. Using an in-plane technique, the needle will be directed toward the iliac crest. After confirmation with 5 mL of isotonic sodium chloride, 20 mL of 0.25% bupivacaine will be injected incrementally with intermittent aspiration. The same procedure will be applied to the other party. A total of 40 mL of 0.25% bupivacaine will be administered.
Control group
Other intervention
All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).

Treatment groups

70 Participants

are divided into 2 treatment groups

Group A: control groupOther 1 intervention

Group B: Quadro iliac plane blockActive comparator 1 intervention

Trial outcomes

Primary outcomes

The primary outcome is the QoR-15 score (0-150 point) at 24 hours postoperatively.

Time frame

24 hours

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Konya City Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now